Granules Life Sciences secures first U.S. FDA approval

Generic drugmaker Granules India subsidiary Granules Life Sciences (GLS), situated in Hyderabad, has acquired U.S. Food and Drug Administration (U.S. FDA) approval for a product that earlier this 12 months was the topic of a pre-approval inspection (PAI).

The GLS facility is now deemed permitted by the U.S. FDA, marking a milestone as Granules India expands its completed dosage manufacturing capabilities. This is the primary FDA approval for the GLS website, the guardian firm stated on Tuesday (November 11, 2025). There was one commentary from the U.S. FDA in the course of the inspection performed between July 28 and August 1. The firm had submitted its response inside the stipulated time, it stated.

Granules eyes foray into peptide section, CDMO enterprise with ₹192 cr. acquisition of Swiss agency 

The firm plans to launch the permitted product within the U.S. market quickly. The product is already permitted and manufactured at Granules’ Gagillapur facility, close to Hyderabad. The new approval will assist strengthen market share and help enterprise continuity by multi-site manufacturing, Granules stated, with out specifying the product.

“We plan on launching the product within the U.S. market quickly. It is an already permitted product at our Gagillapur facility, however we plan on constructing market share with this approval,” Granules India CMD Krishna Prasad Chigurupati stated in a launch.

There are additionally different merchandise filed from the identical website and anticipate the U.S. FDA to approve them following crucial audits if required. “The growth marks the primary approval from Granules’ second Hyderabad facility with completed dosage capabilities,” he stated.